MX2017005260A - Bifidobacterias activadas y metodos de uso de las mismas. - Google Patents

Bifidobacterias activadas y metodos de uso de las mismas.

Info

Publication number
MX2017005260A
MX2017005260A MX2017005260A MX2017005260A MX2017005260A MX 2017005260 A MX2017005260 A MX 2017005260A MX 2017005260 A MX2017005260 A MX 2017005260A MX 2017005260 A MX2017005260 A MX 2017005260A MX 2017005260 A MX2017005260 A MX 2017005260A
Authority
MX
Mexico
Prior art keywords
methods
activated bifidobacteria
bifidobacteria
activated
composition
Prior art date
Application number
MX2017005260A
Other languages
English (en)
Inventor
Kyle David
Mills David
FREEMAN-SHARKEY Samara
Original Assignee
Evolve Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55761664&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017005260(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Evolve Biosystems Inc filed Critical Evolve Biosystems Inc
Publication of MX2017005260A publication Critical patent/MX2017005260A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745Bifidobacteria
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/12Fermented milk preparations; Treatment using microorganisms or enzymes
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135Bacteria or derivatives thereof, e.g. probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04Preserving or maintaining viable microorganisms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00Lactic or propionic acid bacteria
    • A23V2400/51Bifidobacterium
    • A23V2400/529Infantis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Algunas modalidades de la invención incluyen una composición y un método para tratar la disbiosis en lactantes. La composición puede incluir una mezcla de bifidobacterias activadas y un oligosacárido complejo, en donde el oligosacárido complejo puede derivarse de una fuente humana o no humana.
MX2017005260A 2014-10-24 2015-10-23 Bifidobacterias activadas y metodos de uso de las mismas. MX2017005260A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462068553P 2014-10-24 2014-10-24
US201562133243P 2015-03-13 2015-03-13
PCT/US2015/057226 WO2016065324A1 (en) 2014-10-24 2015-10-23 Activated bifidobacteria and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2017005260A true MX2017005260A (es) 2018-01-30

Family

ID=55761664

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005260A MX2017005260A (es) 2014-10-24 2015-10-23 Bifidobacterias activadas y metodos de uso de las mismas.

Country Status (10)

Country Link
US (2) US10716816B2 (es)
EP (1) EP3209308B1 (es)
CN (2) CN107249611A (es)
AU (2) AU2015335601A1 (es)
BR (1) BR112017008284A8 (es)
CA (1) CA2965663C (es)
DK (1) DK3209308T3 (es)
MX (1) MX2017005260A (es)
SG (2) SG11201703298SA (es)
WO (1) WO2016065324A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
AU2015335601A1 (en) 2014-10-24 2017-06-01 Evolve Biosystems Inc. Activated bifidobacteria and methods of use thereof
EP3881680A1 (en) 2014-10-31 2021-09-22 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment
NO3193901T3 (es) 2014-12-23 2018-09-01
DK3065748T3 (da) 2014-12-23 2018-01-29 4D Pharma Res Ltd En bacteroides thetaiotaomicron stamme og dens anvendelse til reduktion af inflammation
WO2016139330A1 (en) * 2015-03-05 2016-09-09 Nestec S.A. Compositions for use in improving stool consistency or frequency in infants or young children
EP3268019A4 (en) * 2015-03-13 2018-10-31 Evolve Biosystems, Inc. Compositions that metabolize or sequester free sugar monomers and uses thereof
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
EP3636272A1 (en) 2015-06-15 2020-04-15 4D Pharma Research Limited Compositions comprising bacterial strains
TW202222339A (zh) 2015-06-15 2022-06-16 英商4D製藥研究有限公司 包含細菌菌株之組合物
SI3650033T1 (sl) 2015-06-15 2022-05-31 4D Pharma Research Limited Sestavki, ki obsegajo bakterijske seve
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MX2018006240A (es) 2015-11-20 2018-08-01 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas.
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
SI3313423T1 (sl) 2016-03-04 2019-07-31 4D Pharma Plc Sestavki, ki vsebujejo bakterijske seve Blautia za zdravljenje visceralne preobčutljivosti
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
US20200046782A1 (en) * 2016-03-11 2020-02-13 Evolve Biosystems Inc. Transient Commensal Microorganism for Improving Gut Health
CN109475169A (zh) 2016-07-01 2019-03-15 进化生物系统股份有限公司 促进哺乳动物免疫系统成熟的方法
TW201821093A (zh) 2016-07-13 2018-06-16 英商4D製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
DK3630136T3 (da) 2017-05-22 2021-05-25 4D Pharma Res Ltd Sammensætninger, der omfatter bakteriestammer
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
EP4104843A1 (en) 2017-06-14 2022-12-21 4D Pharma Research Limited Compositions comprising bacterial strains
LT3638271T (lt) 2017-06-14 2021-01-11 4D Pharma Research Limited Kompozicijos, apimančios bakterines padermes
CN107365705B (zh) * 2017-07-14 2021-01-12 江苏微康生物科技有限公司 一种油溶性益生菌冻干菌粉的冻干保护剂及其应用
EP3675882A4 (en) 2017-08-30 2021-07-28 Pendulum Therapeutics, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
EP3681521A4 (en) * 2017-09-13 2021-05-19 Evolve Biosystems Inc. METABOLOMIC REVIEW OF MAMMAL INFANTS
WO2019143871A1 (en) 2018-01-17 2019-07-25 Evolve Biosystems, Inc. Activation of conditionally-expressed oligosaccharide pathways during fermentation of probiotic strains
EP3801557A4 (en) * 2018-05-30 2022-03-09 Evolve Biosystems Inc. COMPOSITIONS AND METHOD OF USE FOR BIFIDOBACTERIUM LONGUM SUBSP. COMPETENT FOR H5
SG11202011817WA (en) * 2018-06-01 2020-12-30 Evolve Biosystems Inc Compositions and methods to promote host defense and stimulate, expand, and/or reset t cell repertoires
US20210161924A1 (en) * 2018-06-19 2021-06-03 Evolve Biosystems, Inc. Novel oligosaccharides for use in prebiotic applications
CN115298499A (zh) * 2020-03-20 2022-11-04 格礼卡姆股份公司 提供固体hmo产品的方法以及由此得到的固体hmo产品
CN111826324A (zh) * 2020-08-05 2020-10-27 厦门惠盈动物科技有限公司 一种鼠李糖乳杆菌菌粉的制备方法
CN114568516A (zh) * 2020-11-30 2022-06-03 内蒙古伊利实业集团股份有限公司 包含长双歧杆菌婴儿亚种与母乳低聚糖的组合物及其应用
CN114568520A (zh) * 2020-11-30 2022-06-03 内蒙古伊利实业集团股份有限公司 包含长双歧杆菌婴儿亚种的婴幼儿配方粉及其应用
CN116615203A (zh) 2020-12-11 2023-08-18 帝斯曼知识产权资产管理有限公司 改进的益生元制剂
IT202100024911A1 (it) * 2021-09-29 2023-03-29 Univ Degli Studi Di Napoli Federico Ii Dipartimento Di Fisica Ettore Pancini Prebiotico a base di "scotta" delattosata per la prevenzione e gestione della disbiosi intestinale

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716615A (en) 1992-02-10 1998-02-10 Renata Maria Anna Cavaliere Vesely Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use
RU2180915C1 (ru) 2001-04-28 2002-03-27 Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского Консорциум бифидобактерий и лактобацилл, используемый для приготовления бактериальных препаратов, заквасок для кисломолочных продуктов, ферментированных и неферментированных пищевых продуктов, биологически активных добавок, предназначенных для коррекции микрофлоры детей в возрасте до 3-х лет
DK1675481T3 (da) * 2003-10-24 2009-01-19 Nutricia Nv Synbiotisk præparat til börn
US20070082087A1 (en) * 2005-10-06 2007-04-12 Schweitzer Biotech Company Ltd. Fermented milk products containing bifidobacterium longum and isomalto oligosaccharide and the process for producing the same
EP1776877A1 (en) * 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
US20110165127A1 (en) 2006-06-09 2011-07-07 Fabiola Masri Dairy-derived probiotic compositions and uses thereof
WO2008033520A2 (en) * 2006-09-15 2008-03-20 The Regents Of The University Of California Bifidobacterial gene sequences and their use
US8197872B2 (en) 2007-05-17 2012-06-12 The Regents Of The University Of California Human milk oligosaccharides to promote growth of beneficial gut bacteria
WO2008153377A1 (en) * 2007-06-15 2008-12-18 N.V. Nutricia Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide
EP2072052A1 (en) * 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
UA32462U (uk) 2008-02-14 2008-05-12 Харьковский Национальный Медицинский Университет Спосіб оцінки ефективності корекції порушень мікробіоценозу кишечнику у дітей молодшого віку з атопічним дерматитом
CA2658440C (en) * 2008-04-04 2016-08-23 Kraft Foods Global Brands Llc Dairy composition with probiotics and anti-microbial system
EP2143341A1 (en) * 2008-07-08 2010-01-13 Nestec S.A. Nutritional Composition Containing Oligosaccharide Mixture
AU2009253281A1 (en) * 2008-05-27 2009-12-03 Nestec S.A. Probiotics to improve gut microbiota
MX349706B (es) * 2008-11-11 2017-08-09 Alimentary Health Ltd Bifidobacterium longum.
WO2010065652A1 (en) 2008-12-02 2010-06-10 Prolacta Bioscience, Inc. Human milk permeate compositions and methods of making and using same
US9649380B2 (en) 2009-01-12 2017-05-16 Pfizer Italia S.R.L. Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin
US8198872B2 (en) 2009-03-10 2012-06-12 Honeywell International, Inc. Starter-generator with improved excitation
US7888062B1 (en) * 2010-02-01 2011-02-15 Microbios, Inc. Process and composition for the manufacture of a microbial-based product
WO2011100979A1 (en) 2010-02-19 2011-08-25 Glycom A/S Production of 6'-o-sialyllactose and intermediates
WO2012009315A2 (en) 2010-07-12 2012-01-19 The Regents Of The University Of California Bovine milk oligosaccharides
EP2465507A1 (en) * 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharide composition for treating skin diseases
EP2465509A1 (en) 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharide composition for treating acute respiratory tract infections
EP2454948A1 (en) * 2010-11-23 2012-05-23 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
EP2658402A1 (en) 2010-12-31 2013-11-06 Abbott Laboratories Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
ES2692533T3 (es) * 2011-02-10 2018-12-04 Nestec S.A. Modulación del crecimiento de las bífidobacterias mediante una combinación de oligosacáridos de la leche humana
US9579353B2 (en) 2011-06-10 2017-02-28 Prothera, Inc. Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
EP3502123B1 (en) * 2012-02-14 2021-10-13 The Regents Of The University Of California A composition comprising free n-glycans or deglycosylated proteins
US10165788B2 (en) 2013-06-17 2019-01-01 The Regents Of The University Of California Methods and compositions for improved digestion of milk oligosaccharides
AU2015335601A1 (en) 2014-10-24 2017-06-01 Evolve Biosystems Inc. Activated bifidobacteria and methods of use thereof
EP3229595B1 (en) 2014-12-12 2021-02-03 The Regents of the University of California Reduction of milk glycans and their degradation products in the neonate gut

Also Published As

Publication number Publication date
AU2021204822A1 (en) 2021-08-05
CA2965663A1 (en) 2016-04-28
CN114376234A (zh) 2022-04-22
SG11201703298SA (en) 2017-05-30
CA2965663C (en) 2023-04-04
AU2015335601A1 (en) 2017-06-01
BR112017008284A2 (pt) 2017-12-19
US10716816B2 (en) 2020-07-21
EP3209308A1 (en) 2017-08-30
DK3209308T3 (da) 2022-10-03
SG10202002593SA (en) 2020-05-28
EP3209308A4 (en) 2018-06-27
BR112017008284A8 (pt) 2023-04-11
CN107249611A (zh) 2017-10-13
WO2016065324A1 (en) 2016-04-28
EP3209308B1 (en) 2022-08-03
US20200397837A1 (en) 2020-12-24
US20170304375A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
MX2017005260A (es) Bifidobacterias activadas y metodos de uso de las mismas.
IL264028A (en) Crispr/cas9-based preparations and methods for the treatment of retinal degeneration
HK1252821A1 (zh) 用於治療具有rtk突變細胞的患者的組合物和方法
PL3212208T3 (pl) Zastosowanie bakterii l. reuteri do zapobiegania lub leczenia dysbiozy mikrobioty we wczesnych fazach życia
IL248193B (en) Preparations for the treatment of nafld and nash
IL266674A (en) Preparations and methods for treating an opioid overdose
HK1246800A1 (zh) 用於營養組合物的寡糖組合物和其製造方法
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
IL271256A (en) Preparations and methods for the treatment of teopathy
IL263218A (en) Compounds and methods for microbiotic therapy
HK1251168A1 (zh) 用於治療和/或預防腫瘤的沙粒病毒和產生具有(改善的)腫瘤消退特性的沙粒病毒的方法
SG10202106240SA (en) Methods and compositions for determining, and for minimizing, the likelihood of development of allergy in infants
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
IL256350A (en) Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders
EP2964750A4 (en) METHOD AND COMPOSITIONS FOR TREATING AND / OR PREVENTING TYPE-1 DIABETES
IL272121A (en) Preparation and methods for the treatment of myopia
PH12017501022B1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
IL251881A0 (en) Preparations for the treatment of acute, post-operative or chronic pain and methods of using them
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
IL257452B (en) Methods and compositions for the treatment of cytoplasmic glycogen storage disorders
EP3139744A4 (en) Methods and compositions for treating and preventing tinnitus
EP3423063A4 (en) COMPOSITIONS AND METHODS FOR TREATING SEARCH OR SUBSTANCE ABUSE MISTAKES
PL3548006T3 (pl) Kompozycja do stosowania w leczeniu zmian jelitowych
DK3313207T3 (en) Compositions and methods for the treatment of malnutrition
MX2016009665A (es) Composiciones y metodos para el tratamiento de la hemorragia cerebral.